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Slymph node-positive patients than the balance of stage I pa-
tients without recurrence. Finally, 1 of the more prominent
studies on this topic was performed by D’Amico and col-
leagues24 who evaluated 171 patients with NSCLC with 7
serum biomarkers (vascular endothelial growth factor, he-
patocyte growth factor, E-selectin, CD44, basic fibroblast
growth factor, urokinase plasminogen activator, and uroki-
nase plasminogen activator receptor) using enzyme-linked
immunosorbent assay. This was accomplished against pre-
and postoperative (serial) blood sampling from patients un-
dergoing complete resection. The Cox proportional hazards
regression analysis showed disease recurrence could be pre-
dicted by decreasing levels of E-selectin (P¼ .002), increas-
ing levels of CD44 (P ¼ .001), and increasing levels of
urokinase plasminogen activator receptor (P¼ .03), with se-
rial sampling after surgery. A study is currently underway in
our laboratory to determinewhether the prognostic accuracy
of our current panel can be improvedwith the findings by the
D’Amico group and an effort to identify new biomarkers us-
ing proteomic methods. Furthermore, we will explore addi-
tional biomarkers for this purpose using both a shotgun
proteomics approach and an approach focused on identify-
ing surrogate biomarkers for the more prominent of the
metastasis-suppressor genes, including NM23, PEBP1,
and KAI1, as reviewed by Shoushtari and colleagues.25CONCLUSIONS
We have reported the development of a serum biomarker
panel for stage I NSCLC patients that predicts recurrence
previously undetected by standard imaging and pathologic
studies. The performance characteristics of this initial ‘‘re-
currence algorithm’’ (77% overall prognostic accuracy for
52 stage I NSCLC patients) were roughly in the same range
as those for PET-CT and quantitative real-time polymerase
chain reaction-based methods for predicting recurrence.
Additional refinement of this panel has the potential to ac-
curately stratify patients for more frequent screening proto-
cols or adjuvant therapy. With validation of this panel
against an external cohort, its true potential to improve
overall survival can be realized.References
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Dr Chuong D. Hoang (Stanford, Calif). I want to congratulate
you and your group on a provocative research effort, and, if your
ongoing work demonstrates that a blood-based test can accurately
predict disease recurrence in early-stage lung cancer, this could begery c December 2012
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San incredible opportunity to identify novel mechanistic insights to
lung cancer development and progression.
I have the following 2 questions based on your presentation.
First, the reasoning for your studies is that occult micrometastases
undetectable at surgery are the primary cause of disease recurrence
in early-stage lung cancer patients. With this in mind, why would
you want to collect blood samples for a predictive biomarker assay
in the preoperative period? The results of the blood assays could be
confounded by the presence of the primary tumor, which might ob-
scure the signal of the micrometastases. Why not collect the blood
samples in the postoperative period when the effects of the primary
tumor are no longer present?
Second, the primary method you used to select your predictive
analyses and the analytes was the Random Forest algorithm. This
classifier tends to work best when the number of input variables is
large, and yet you only tested 43 biomarkers for this study. What
were the selection criteria you used for including these potential
biomarkers? Also, this algorithm suffers sometimes from overfit-
ting of the data, which can lead to near-perfect classifier results,
and I noticed that you showed relatively lower sensitivity, specific-
ity, and accuracy in your final analysis.
Again, I really look forward to seeing your validation studies on
this interesting project. I thank you for the opportunity to discuss it.
Dr Rinewalt. Thank you, Dr Hoang, for your input and for your
questions.
To answer your first question, we chose to do these preopera-
tively because this was based on our previous discovery efforts.
We know that these tumor antigens typically fall into 3 categories:
aberrant isoforms of commonly expressed proteins, overexpres-
sion of common proteins, or proteins specific to the tumor itself,
the latter of which is what most of us are specifically interested
in targeting for either diagnosis or treatment. These are typically
only present in minuscule quantities, even from the primary tumor.
We hypothesized that wewould obtain a greater degree of sensitiv-
ity by doing assays at this time for the circulating autoantibodies to
the tumor instead of the tumor antigens directly, given the large
signal implication produced by the B cells of the body’s own hu-
moral response. Additionally, autoantibodies are thought to only
be produced early on in the disease process.
We selected these biomarkers for the study using 2 methods.
The first was based on reviews of the published data for biomarkers
that had previously demonstrated some efficacy for the early de-
tection of lung cancer. The second was based on our previous dis-
covery efforts in our laboratory, headed by Drs Michael Liptay and
Jeffrey Borgia. Specifically, we used Western blots prepared fromThe Journal of Thoracic and Cara lung adenocarcinoma cell line and then probed these with pooled
serum from non–small cell lung cancer patients, 1 without nodal
disease and 1 with nodal disease. We compared these and identi-
fied them using mass spectrometry to choose this list of
biomarkers.
To answer your questions about the Random Forest, it is a very
complicated multivariate statistical method. You are correct in that
it has been shown in the published data to be a robust and highly
accurate when one is analyzing data with a large number of inputs,
and we did have 43 biomarkers. Less noise is present when analyz-
ing this type of data. We believe that this will have resulted in less
overfitting of the data than, say, using just a classification tree, be-
cause the Random Forest will use approximately 1000 trees and
then average their results.
Dr Raphael Bueno (Boston, Mass). I congratulate you on your
paper.
I have 2 questions. One, you are looking for survivors versus pa-
tients likely to develop recurrence so you can affect treatment, so I
would expect your curves, the split curve, to look as a curve would
with survival at 5 years of 95% and a curve with survival of 20% at
5 years, which is really what you need achieve. Any comments on
that?
Second, we do not live in isolation. The pathologists have de-
fined, and we have defined, during the past 3 decades, as surgeons,
prognostic factors from studying the tumor, from the differentia-
tion, from the T status, for lymphovascular invasion, et cetera,
that are well established, and any prognostic test needs to be put,
as a part of that, in the context of that to bring an additional piece
of information. You do not merely want to recapitulate T1 versus
T2. Have you considered both issues?
Dr Rinewalt. Thank you for your comments, Dr Bueno.
To answer your first question, I agree that ultimately the goal is
to try to prognosticate these patients, and so we would hope that at
some point we will be able to develop a curve with which we can
predict who will develop recurrence and hopefully stratify them
into a new treatment that will shift that first curve up. The patients
who present with distant disease will probably continue to do
poorly; however, this was not the goal of our study. We are hoping
that by being able to intervene early on in the process that we can
shift that survival curve up.
To answer your second question, we have not specifically put
these together with all of the clinical factors, although I think ulti-
mately studying all the data that we have, including PET data, tu-
mor size, and histologic type, this will be a companion test and not
something that will stand alone.diovascular Surgery c Volume 144, Number 6 1351
